Accession Number:

ADA599938

Title:

Clinical Trial of AC105 (Mg/PEG) for Treatment of Acute Spinal Cord Injury (SCI). Phase 2

Descriptive Note:

Annual rept. 30 Sep 2012-29 Sep 2013

Corporate Author:

ACORDA THERAPEUTICS INC HAWTHORNE NY

Personal Author(s):

Report Date:

2013-10-01

Pagination or Media Count:

11.0

Abstract:

Acorda Therapeutics, Inc. is developing the polymer formulation of magnesium, known as AC-105, for the treatment of acute spinal cord injury. This trial is partially supported by the funds from this Department of Defense Broad Agency Announcement for Extramural Medical Research grant. The primary hypothesis of this proposed study is that treatment of people with acute SCI with AC-105 will result in greater normalization of CNS Mg than treatment with MgCl2 or saline solutions and potentially improve neurological outcome from injury.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE